Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2010 Apr 14;2010(4):CD006562.
doi: 10.1002/14651858.CD006562.pub2.

5-FU for genital warts in non-immunocompromised individuals

Claudio S Batista  1 , Alvaro N Atallah, Humberto Saconato, Edina Mk da Silva
Affiliations
Meta-Analysis

5-FU for genital warts in non-immunocompromised individuals

Claudio S Batista et al. Cochrane Database Syst Rev. .

Abstract

Background: Genital warts are common and usually are harmless but can be painful and psychologically burdensome. Several local treatments can be used, including topical 5-Fluorouracil (5-FU).

Objectives: To determine the effectiveness and safety of 5-FU topical treatment for genital warts in nonimmunocompromised individuals.

Search strategy: Databases searched were Cochrane Central Register of Controlled Trials (The Cochrane Library 2009 Issue 3), MEDLINE (1966 to August 2009), EMBASE (until August 2009), LILACS (1982 to August 2009). The search had no language or publication restrictions.

Selection criteria: The review included randomised controlled trials (RCTs) among women, men, or both sexes, aged 18 years and older, comparing: 5-FU versus placebo or no treatment; 5-FU in any dose versus other isolated treatment, topical or systemic; 5-FU in any dose associated with other treatment versus placebo; 5-FU in any dose associated with other treatment versus other isolated treatment, topical or systemic; 5-FU in any dose associated with other treatment versus other associated treatment, topical or systemic.

Data collection and analysis: Two authors independently assessed trial quality and extracted data from the original publications.

Main results: Six trials involving 988 patients (645 women and 343 men) and reporting eight comparisons were found. Two studies reported withdrawals and dropouts, but none mentioned analysis by intention to treat (ITT). 5-FU presented better results for cure than placebo or no treatment (relative risk (RR) 0.39, 95% confidence interval (CI) 0.23 to 0.67), meta-cresol-sulfonic acid (MCSA) (RR 2.11, 95% CI 0.83 to 5.37), Podophylin 2%, 4% or 25% (RR 1.26, 95% CI 0.86 to 1.82). There were no statistical differences for treatment failure for 5-FU versus CO2 Laser (RR 0.69, 95% CI 0.43 to 1.11) versus 5-FU + INFalpha-2a (low dose) (RR 1.02, 95% CI 0.87 to 1.119). Worse results were found for 5-FU versus 5-FU + INFalpha-2a (high dose) (RR 10.78, 95% CI 1.50 to 77.36), and 5-FU + CO2 Laser INFalpha-2a (high dose) (RR 7.97, 95% CI 2.87 to 22.13).

Authors' conclusions: The reviewed trials were highly variable in methods and quality, and the evidence provided by these studies was weak. Cure rates with several treatments were variable, and although 5-FU presents therapeutic results that are inferior to those seen with 5-FU + Inf alpha-2a (high dose) and 5-FU + CO2 Laser + Inf alpha-2a (high dose), the treatment should not be abandoned. Topical treatment with 5-FU has a therapeutic effect; however, the benefits and risks have not been determined clearly and further studies are needed.

PubMed Disclaimer

Conflict of interest statement

No declaring

Update of

  • doi: 10.1002/14651858.CD006562

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Botacini 1993 {published data only}
    1. Botacini DDG, Valente MN, Lascasa RC, Batista KJ, Rodrigues DLG. Therapeutic of cervicovaginal human papillomavirus infection. Randomized study with four drugs [Tratamento da infecção por papilomavirus humano(HPV). Estudo aleatorizado com quatro fármacos]. J Bras Ginecol 1993; 103(6):205-10.
Carpinelo 1988 {published data only}
    1. Carpinello VL, Mallory TR, Sedlacek TV, Zderic SA. Results of carbon dioxide laser therapy and topical 5-fluorouracil treatment for subclinical condylomata found by magnified penile surface scanning. J Urol 1988; 140(1):53-4. - PubMed
Relakis 1996 {published data only}
    1. Relakis K, Cardamakis E, Korantzis A, Matalinos K, Mantavoulos H. Treatment of men with flat (FC) and acuminata (CA) condylomata with interferon alpha-2a. Eur J Gynecol Oncol 1996; 17(6):529-33. - PubMed
Syed 2000 {published data only}
    1. Syed TA, Qureshi ZA, Ahmad SA, Ali SM. Management of intravaginal warts in women with 5-fluorouracil (1%) in vaginal hydrofilic gel: a placebo controlled double blind study. Int J STD AIDS 2000; 11(6):371-4. - PubMed
Wallin 1977 {published data only}
    1. Wallin J. 5-Fluorouracil in the treatment of penile and urethral condyloma acuminata. Br J Vener Dis 1977; 53(4):240-3. - PMC - PubMed
Weismann 1982 {published data only}
    1. Weismann K, Kassis V. Treatment of condyloma acuminatum with 0,5% 5-Fluorouracil. A double blind clinic trial [Behandlung von Condyloma acuminatum mit 0,5% 5-Fluorouracil. Lösing Eine doppeblind-clinische Untersucchung]. Z Hautkr 1982; 57(11):s10-6. - PubMed

References to studies excluded from this review

Bergman {published data only}
    1. Bergman A, Nalick R. Genital human pappilomavirus infection in men. Diagnosis and treatment with a laser and 5-Fluorouracil. J Reprod Med 1991; 36(5):363-6. - PubMed
Bringel {published data only}
    1. Bringel PJ, Andrade Arruda R. 5-fluorouracil cream 5% in the treatment of intraurethral condylomata acuminata. Br J Urol 1982; 54(3):295. - PubMed
Brodman {published data only}
    1. Brodman M, Dottino P, Friedman F Jr, Heller D, Bleiweiss I, Sperling R. Human papillomavirus-associated lesions of the vagina and cervix. Treatment with a Laser and Topical 5-fluorouracil. J Reprod Med 1992; 37(5):453-6. - PubMed
Cardamakis {published data only}
    1. Cardamakis E, Relakis P, Ginopoulos P, Korantzis A, Metalinos E, Sthatopoulos E, Papathanasiou Z, Michopoulos J, Montavoulos H, Kotoulas L-G, Tzingounis V. Treatment of penile intraepithelial neoplasias (PIN) with interferonAlpha-2a, CO2,laser(vaporization) and 5-Fluorouracil 5%(5-Fu). Eur J Gynecol Oncol 1997; 18(5):410-3. - PubMed
Cardamakis 1 {published data only}
    1. Cardamakis E, Kotoulas IG, Matalinos K, Relakis K, Scarpari M, Korantzis A, Papathanasiou Z. Treatment of urethral condylomata acuminata or flat condylomata with interferon -alpha 2a.. J Urol 1994; 152(Pt 1):2011-13. - PubMed
Djawari {published data only}
    1. Djawari D. Treatment of condyloma acuminata with 5-fluorouracil [5-Fluoro-Uracil-Behandlung der Condylomata acuminata]. Z Hautkr 1986; 61(7):463-9. - PubMed
Dretler {published data only}
    1. Dretler SP, Klein LA. The eradication of intraurethral condyloma acuminata with 5 per cent 5-fluorouracil cream. J Urol 1975; 113(2):195-8. - PubMed
Emokpare {published data only}
    1. Emokpare NA. Observations on a Clinico-Therapeutic with topical 5-fuor-uracil (Efudix) in condylomata acuminata.. Dermatol Manatsschr 1975; 161(12):1019-21. - PubMed
Ferenczy {published data only}
    1. Ferenczy A. Comparison of 5-fluorouracil and CO2 Laser for treatment of vaginal condylomata. Obstet Gynecol 1984; 64(6):773-8. - PubMed
Halasz {published data only}
    1. Halasz CL. Treatment of warts with topical pyruvic acid: with and without added 5-Fu. Cutis 1988; 62(6):283-5. - PubMed
Hursthouse {published data only}
    1. Hursthouse MW. A controlled trial on the use of topical 5-fluorouracil on viral warts. Br J Dermatol 1975; 92(1):93-6. - PubMed
Husseinzadeh {published data only}
    1. Husseinzadeh N, Guoth JG, Jayawardena DS. Subclinical cervicovaginal human papillomavirus infections associated with cervical condylomata and dysplasia. Treatment outcomes. J Reprod Med 1994; 39(10):777-80. - PubMed
Klutke {published data only}
    1. Klutke JJ, Bergaman A. Interferon as an adjuvant treatment for genital condyloma acuminatum. Int J Gynaecol Obstet 1995; 49(2):171-4. - PubMed
Krebs {published data only}
    1. Krebs H-B, Church F. Treatment of extensive vulvar condylomata acuminata with topical 5-Fluororuracil.. South Med J 1991; 83(7):761-4. - PubMed
Krebs 1 {published data only}
    1. Krebs HB. Management of human papillomavirus-associated genital lesions in men.. Obstet Gynecol 1989; 73(3 (Supl Pt 1)):321-6. - PubMed
Krebs 2 {published data only}
    1. Krebs HB. Combination of laser plus 5-fluorouracil for the treatment of extensive genital condylomata acuminata.. Lasers Surg Med 1988; 8(2):135-8. - PubMed
Krebs 3 {published data only}
    1. Krebs HB. Treatment of vaginal condylomata acuminata by weekly topical application of 5-fluorouracil.. Obstet Gynecol 1987; 70(1):68-71. - PubMed
Krebs 4 {published data only}
    1. Krebs HB. Prophylatic topical 5-fluorouracil following treatment of human papillomavirus-associated lesions of the vulva and vagina. Obstet Gynecol 1986; 68(6):837-41. - PubMed
Lopes {published data only}
    1. Lopes CF, Armond S. Therapeutic trial with 5-fluorouracil ointment [Ensaio terapêutico com pomada de 5-fluorouracil]. Hospital (Rio J) 1970; 77(4):1275-80. - PubMed
Moore {published data only}
    1. Moore GE, Norton LW, Meiselbaugh DM. Condyloma. A new epidemic.. Arch Surg 1978; 113(5):630-1. - PubMed
Netto Junior {published data only}
    1. Netto Junior NR, Montellato NI, Srougi M, Rangel PE, Goes GM. Treatment of condylomata acuminata with 5-fluoruracil [Tratamento do condiloma acuminado com 5-fluorouracil]. AMB Rev Assoc Med Bras 1977; 23(3):91-2. - PubMed
Pride {published data only}
    1. Pride GL. Treatment of large lower genital tract condylomata with topical 5-Fluorouracil.. J Reprod Med 1990; 35(4):384-7. - PubMed
Schimidt {published data only}
    1. Schimidt H, Jacobsen FK. Double -Blind Randomized Clinical Study on Treatment of Warts with a Fluorouracil-Containing Topical Preparation [Ergebnis einer doppelblind und randomisiert durchgeführten klinischen Studie eines neuen Warzenmittels auf Basis Fluorouracil]. Z Hautkr 1981; 56(1):41-3. - PubMed
Stefanon {published data only}
    1. Stefanon B, Palluca A, Merola M, Bandieramonte G. Treatment with 5-Fluorouracil of 35 patients with clinical or subclinical HPV. Eur J Gynecol Oncol 1996; 17(6):534. - PubMed
von Krough {published data only}
    1. Von Krough G. 5-Fluoro-Uracil cream in the successful treatment of therapeutically refractory condylomata acuminata of the urinary meatus. Acta Derm Venereol 1976; 56(4):297-301. - PubMed
Zarcone {published data only}
    1. Zarcone R, Carfora E, Bellini P, Vicinanza G. Drug therapy of condylomata acuminata [Trattamento farmacologico dei condilomi acuminati]. Minerva Ginecol 1996;48(48):7-8. 1996; 48(48):7-8. - PubMed

Additional references

Aaltonen 2002
    1. Aaltonen LM, Rihkanen H, Vaheri A. Human papillomavirus in larynx. Laryngoscope 2002; 112:700-7. - PubMed
Adler 1985
    1. Adler MW, Mindel A. Genital infections. Med Bull 1985; 41:361-6.. - PubMed
Anderson 1985
    1. Anderson FE. Warts: fact and fiction. Drugs 1985; 30:368-75. - PubMed
Brodsky 1987
    1. Brodsky L, Siddiqui SY, Stanievich JF. Massive oropharyngeal papillomatosis causing obstructive sleep apnea in a child. Arch Otolaryngol Head Neck Surg 1987; 113:882-4.. - PubMed
Butel 2000
    1. Butel JS. Viral carcinogenesis: revelation of molecular mechanisms and etiology of human disease. Carcionogenesis 2000; 21(3):405-26.. - PubMed
Byrne 1987
    1. Byrne JC, Tsao MS, Fraser RS, Howley PM. Human papillomavirus-11 DNA in a patient with chronic laryngotracheobronchial papillomatosis and metastatic squamous-cell carcinoma of the lung.. N Engl J Med 1987; 317:873-8. - PubMed
Christiansen 1984
    1. Christiansen PL, Jorgensen K, Grontved A. Juvenile papillomatosis of the larynx.. Acta Otolaryngol [Stockh] 1984; 412(Suppl):37-9..
Clarke 2002
    1. Clarke M, Oxman AD. Cochrane Collaboration Handbook. 4.1.5 edition. Vol. 4.1.5; Section 4. Oxford.: Cochrane Reviewers Handbook inThe Cochrane Library, 2002.
Conejo 2001
    1. Conejo PR, Puerto MJM, Soto AM, Martinez AM, Sanz MAV. Recurrent respiratory papillomatosis: a cause of progressive respiratory distress [Papilomatosis respiratoria recurrente: una causa de dificultad respiratoria progresiva]. An Esp Pediatr 2001; 55(6):558-60. - PubMed
Davis 1989
    1. Davis AJ, Emans SJ. Human papilloma virus infection in the pediatric and adolescent patient. J Pediatr 1989; 115:1-9. - PubMed
Dickersin 1994
    1. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews.. BMJ 1994; 309((6964)):1286-91. - PMC - PubMed
Dyment 1996
    1. Dyment PG. Human Papillomavirus Infection: Reprint from State of the Art Reviews. Adolescent Medicine 1996; 7(1):119-30. - PubMed
Fletcher 1991
    1. Fletcher JL. Perinatal transmission of human papillomavirus. American Family Physician Jan,1991;43 (1):143-8. - PubMed
Gibbs 2006
    1. Gibbs S, Harvey I, Sterling JC, Stark R. Local treatments for cutaneous warts (Cochrane Review). Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: ]
Higgins 2002
    1. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 2002; 21(11):1539-58. - PubMed
Ho 2002
    1. Ho GY, Studentsov Y, Hall CB, et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV- 16 virus-like particles. Journal of Infectious Diseases 2002; 186(6):737-42. - PubMed
Kashima 1987
    1. Kashima HK, Shah K. Recurrent respiratory papillomatosis: clinical overview and management principles. Obstet Gynecol Clin North Am 1987; 14:581-8. - PubMed
Kashima 1996
    1. Kashima HK, Mounts P, Shah K. Recurrent respiratory papillomatosis. Obstet Gynecol Clin North Am 1996; 23:699-706. - PubMed
Kloetzel 1999
    1. Klotzel K. Medicina ambulatorial: princípios básicos.. 1° edition. Vol. 1. São Paulo: EPU, 1999.
Koliopoulos 2006
    1. Koliopoulos G, Martin-Hirsch P, Paraskevaidis E, Arbyn M. HPV testing versus cervical cytology for screening for cancer of the uterine cervix (Protocol for a Cochrane Review). Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD004709 ]
Koutsky 1998
    1. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiological Review 1998; 10:122-63. - PubMed
L`Abbe 1987
    1. L'Abbe KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research.. Ann Intern Med 1987; 107((2)):224-33.. - PubMed
Lamagni 1998
    1. Lamagni TL, Hughes G, Rogers PA, et al. New cases seen at genitourinary medicine clinics. Commun Dis Rep England 1998;9(Suppl ):S1-12.:S1-12. [CDR Suppl. 1999] - PubMed
Machado 2000
    1. Machado AED. Photodynamic therapy: principles, potential of application and perspectives [Terapia fotodinâmica: princípios, potencial de aplicação e perspectivas]. Quim. Nova 2000; 23:237.
Mayo Clinic 2005
    1. Mayo Clinic. Genital warts [Genital warts]. Mayo Foundation for Medical Education and Research (MFMER). <<http://health.yahoo.com/topic/sexualhealth/overview/article/mayoclinic/ CAEC99AC-77E1-414C-B0A8ACFA312F2E1E>> accessed 04-12-06 2005.
Merck's 2005
    1. Merck's Investigational Human Papillomavirus. HPV- Vaccine Reduced Infection and Disease in New Clinical Study - Business Wire. <<http://www.findarticles.com/p/articles/mi_m0EIN/is_2006_Nov_1>> accessed 12-25-06 April 6, 2005.
Merck's 2006
    1. Merck's Cervical Cancer Vaccine. GARDASIL®, Added to the CDC Vaccines for Children Contract - Business Wire. <<http://www.findarticles.com/p/articles/mi_m0EIN/is_2006_Nov_1>> accessed 12-25-06 Nov 1, 2006.
Moore 2001
    1. Moore RA, Edwards JE, Hopwood J, Hicks D. Imiquimod for the treatment of genital warts: a quantitative systematic review [Imiquimod for the treatment of genital warts: a quantitative systematic review]. BMC Infectious Diseases 2001; 1(3 doi:10.1186/1471-2334):1-3. - PMC - PubMed
Mougin 2001
    1. Mougin C, Dalstein V, Pretet JL, Gay C, Schaal JP, Riethmuller D. Epidemiology of cervical papillomavirus infections. Recent knowledge. Presse medicale 2001; 30(20):1017-23. - PubMed
Munoz 2003
    1. Munoz N, Bosch FX, Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518–27. - PubMed
Murad 1996
    1. Murad AM. Oncology: Clinical bases of the Treatment. In: Murad AM, Katz A. Oncologia: Bases Clínicas do Tratamento. 1st edition. Rio de Janeiro: Guanabara Koogan, 1996.
Oliveira 2002
    1. Oliveira RB, Alves RJ. Bioreductive antineoplastic agents: A new approach to the treatment of solid tumors [Agentes Antineoplásicos Biorredutíveis: Uma nova alternativa para tratamentos de tumores sólidos]. Quim. Nova 2002; 25:976.
Onnez 1995
    1. Onnez W, Reichman RC. Papillomaviruses. In: Mandell GL, Bennet JE, Dolin R, eds. Principles and Practice of Infectious Diseases. New York: Churchill Livingstone, 1995:1387-400..
Oriel 1971
    1. Oriel JD. Natural history of genital warts. Br J Vener Dis 1971; 47:1-13. - PMC - PubMed
PATH 2005
    1. PATH. HPV and Cervical Cancer: Unique Challenges and Opportunities for Disease Prevention. PATH July, 2005.
Pride 1990
    1. Pride GL. Treatment of large lower genital tract condylomata acuminata with topical 5-fluorouracil. J Reprod Med 1990; 35:384-7. - PubMed
Reid 1990
    1. Reid R, et al. Superficial laser vulvectomy IV: Extended laser vaporization and adjunctive 5-fluorouracil therapy of human papillomavirus-associated vulvar disease. Obstet Gynecol 1990; 76:439-48. - PubMed
Roman 1986
    1. Roman A, File K. Human papillomavirus DNA associated with foreskins of normal newborns. J.Infect Dis 1986; 153:855-8. - PubMed
Sanclemente 2002
    1. Sanclemente G, Gill DK. Human Papillomavirus molecular biology and pathogenesis. Journal of the European Academy of Dermatology and Venereology 2002; 16:231-40. - PubMed
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273:408-12. - PubMed
Schwartz 1987
    1. Schwartz DB, Greenberg MD, Dauod Y, Reid R. The management of genital condylomas in pregnant women. Obstet Gynecol Clin North Am 1987; 14:589-99.. - PubMed
Sedlacek 1989
    1. Sedlacek TV, Sindheim S, Eder C et al. Mechanism of human papillomavirus transmission at birth. Am J. Obstet Gynecol 1989; 161:55-9. - PubMed
Shah 1986
    1. Shah K, Kashima H, Polk BF, Shah F, Abbey H, Abramson A. Rarity of cesarean delivery in cases of juvenile-onset respiratory papillomatosis. Obstet Gynecol 1986; 68:795-9. - PubMed
Smith 1991
    1. Smith EM, Johnson SR, Pgnatari S, Crupe TP, Twek L. Perinatal vertical transmission of human papillomavirus and subsequent development of respiratory tract papillomatosis. Ann Otol Rhinol Laryngol 100 1991; 100:479-83. - PubMed
Steinberg 1988
    1. Steinberg BM. Papilloma virus: effects on mother and child. In: Kundsin RB, Falk L, Hipp SS, eds. Impact on the fetus of parental sexually transmitted disease. New York: New York Academy of Sciences, 1988:118-28. - PubMed
Sterling 1998
    1. Sterling JC, Kurtz JB. Viral infections. In: Champion RH, Burton JL, Burns DA, Breathnach SM, editor(s). Rook Textbook of Dermatology. 6th edition. Oxford: Blackwell Scientific Publications Ltd, 1998.
Sykes 1995
    1. Sykes NL. Codyloma acuminatum. Int J Dermat 1995; 34:297-302. - PubMed
Vancurova 2002
    1. Vancurova I, Wu R, Miskolci V, Sun S. Increased p50/p50 NF-KB activation in human papillomavirus type 6- or type 11-induced laryngeal papilloma tissue. J Virol 2002; 76(3):1533-6. - PMC - PubMed
Woodman 2001
    1. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357:1831-6. - PubMed

MeSH terms